17,261 trials
Ichthyosis · Autosomal Recessive Congenital Ichthyosis · Lamellar Ichthyosis
Primary: Reduction at Week 16 in the Ichthyosis Area Severity Index (IASI) — 2.4; 4.3 units on a scale
Lung Diseases, Interstitial · Systemic Sclerosis · Scleroderma
Primary: Number of Participants With Serious Adverse Events — 0.33; 0.25 Number of Participants with Serious Adve
Fontan
Primary: Number of Participants Who Experience an Adverse Reaction to the Study Medication During the Study Enrollment Period. — 16 Participants
Respiratory Distress Syndrome, Newborn
Primary: Number of Participants With Adverse Events as a Measure of Safety and Feasibility — 3; 8; 4; 12 Participants
Acute Myocardial Infarction
Primary: Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation — 21; 21 Count of participants — p=<0.001
Hepatitis B
Primary: Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects…
COVID-19 · Sars-CoV2
Primary: Mechanical Ventilation or Death Endpoint — 2; 0 Participants
Acute Myeloid Leukemia (Relapsed/Refractory)
Primary: Number of Participants With CR/CRi = Overall Reponse Rate — 15; 6 Participants
Multiple System Atrophy
Primary: TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) — 52; 28; 49; 21 events
Colorectal Neoplasm
Primary: Number of Participants With Best Objective Response Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With…
IgG4-related Disease
Primary: Treatment Response — 3 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Trough Forced Expiratory Volume in One Second (FEV1) Response After 24 Weeks — -0.034; 0.044; 0.066; 0.087 litre
Chronic Spontaneous Urticaria
Primary: Change From Baseline of Weekly Urticaria Activity Score (UAS7) at Week 24 — -20.36; -22.50; -21.26 Score on a scale
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Assisted Epistaxis Severity Scale (aESS) Score From Baseline at 8 Week Follow-up — 2.32; 1.96 units on a scale
Gingival Inflammation and Bleeding · Dental Plaque
Primary: Mean Within-Treatment Whole-Mouth Score - Gingival Efficacy — 2.081; 2.094; 2.092; 1.996 units on a scale